Regenerative medicine company Orthocell (ASX:OCC) has submitted an application to the Thai Food and Drug Administration for its leading nerve repair product, Remplir. …
Latest Video
New Stories
-
Orthocell submits for Remplir regulatory approval in Thailand
February 24, 2025 - - Australian Biotech -
AdPha welcomes commitment to expand access to bulk-billing incentive
February 24, 2025 - - Latest News -
New Zealand medtech start-up Avasa hits milestone in development of world’s first arterial coupler
February 24, 2025 - - Other Health -
Neuren receives rare paediatric disease designation from the US FDA
February 24, 2025 - - Australian Biotech -
High profile Australians expose the painful reality of shingles in awareness week
February 24, 2025 - - Latest News -
Fix the language, accept the political discomfort it will cause, or forget about meaningful change
February 24, 2025 - - Latest News -
Ovarian Cancer Australia says new report highlights the need for action
February 24, 2025 - - Latest News